Alongside regulations from the IRA, oncology R&D is set to face unique challenges when MFN is enforced.

Madeline Verbeke, Senior Clinical Advisor, MIIT, touches on injectable and oral GLP-1's impact on the clinical landscape, and the clinical and scientific hurdles oral GLP-1 formulations need to ...

Rob DeWig, VP of Healthcare Sales at Inmar, touched on the current operational challenges that health system pharmacies face.

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction ...

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery ...

FDA denies approval for Rexulti in PTSD treatment, citing insufficient evidence despite clinical trials. Otsuka and Lundbeck plan next steps.

Pfizer acquires Metsera for $4.9 billion, enhancing its portfolio in obesity and cardiovascular treatments with innovative ...

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims ...

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and ...

Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the ...